Mr. Joseph is on a Leave of Absence from Foley & Larder LLP.  He is currently serving as the Chief Regulatory Counsel of Intrivo Diagnostics.

Paul Joseph is of counsel in Foley & Lardner LLP’s Washington, D.C. office and a member of firm’s Government Solutions Practice. Joseph previously was an associate chief counsel for enforcement at the U.S. Food and Drug Administration (FDA). During his time at the FDA, Paul worked closely with the Office of Criminal Investigations at the U.S. Department of Justice (DOJ), and other government agencies to investigate and prosecute violations of the Federal Food, Drug, and Cosmetic Act. He was also involved in numerous health care fraud matters and False Claims Act investigations involving FDA regulated drugs, medical devices, food, dietary supplements, and biologics.

Paul’s experience tied with his depth of knowledge across government agencies, enables him to be a tremendous asset to Foley’s team of attorneys who represent clients in FDA enforcement matters and government investigations, and monitor emerging FDA priorities and trends.

Prior to joining the FDA, Paul was a trial attorney for the justice department for almost 20 years. He worked on civil and criminal investigations, and handled international legal compliance issues. At the justice department, he held several positions in these four sections of the criminal division: 1) Narcotic and Dangerous Drug Section, 2) the Asset Forfeiture and Money Laundering Section, now known as the Money Laundering and Asset Recovery Section 3) the Office of International Affairs, and 4) the Office of Enforcement Operation.

Paul was also a prosecutor at the U.S. Attorney’s office in the District of Columbia.

Speeches, Publications, and Articles

  • Speaker, "Exploring Advanced Topics in Food and Drug Law," Food and Drug Law Institute's (FDLI) Annual Conference (October 8, 2020)
  • Speaker, “Potential Marketing and Sales Liabilities in the Pharma and Medical Devices Sector,” Health Law Network, Association of Corporate Counsel, (June 2, 2020)
  • Speaker, “What is Next for the FDA on CBD Regulatory Policies?,” Law Over Lunch series, Food and Drug Law Institute, (May 27, 2020)
  • Panelist, “Cannabis and CBD Regulatory Update: Where We Are and What's Next,” Food and Drug Law Institute, Washington D.C., (May 8, 2020)
  • Author, “Cannabis Infusion Remains Hot Trend, But Will FDA Throw Cold Water on it?,” The Food Institute Report (March 30, 2020)


  • Boston College Law School (J.D.)
  • Boston College (B.A)


  • Awarded, Campbell Scholarship for Public Service
  • Recipient, U.S. Attorney General’s John Marshall Award for Outstanding Legal Achievement in Litigation
  • Recipient, FDA Honors Award for demonstrated collaboration in connection with the successful seizure and destruction of thousands of unapproved and misbranded drug products


  • District of Columbia
  • Circuit Court of Appeals, District of Columbia